- Home
- GMAB vs OKTA Comparison
GMAB vs OKTA Comparison
Compare GMAB & OKTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- OKTA
- Stock Information
- Founded
- GMAB 1999
- OKTA 2009
- Country
- GMAB Denmark
- OKTA United States
- Employees
- GMAB N/A
- OKTA N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- OKTA Computer Software: Prepackaged Software
- Sector
- GMAB Health Care
- OKTA Technology
- Exchange
- GMAB Nasdaq
- OKTA Nasdaq
- Market Cap
- GMAB 15.4B
- OKTA 15.8B
- IPO Year
- GMAB N/A
- OKTA 2017
- Fundamental
- Price
- GMAB $28.61
- OKTA $91.96
- Analyst Decision
- GMAB Buy
- OKTA Buy
- Analyst Count
- GMAB 6
- OKTA 40
- Target Price
- GMAB $37.60
- OKTA $120.97
- AVG Volume (30 Days)
- GMAB 1.4M
- OKTA 4.5M
- Earning Date
- GMAB 11-05-2025
- OKTA 08-26-2025
- Dividend Yield
- GMAB N/A
- OKTA N/A
- EPS Growth
- GMAB 77.72
- OKTA N/A
- EPS
- GMAB 21.62
- OKTA 0.84
- Revenue
- GMAB $3,646,881,232.00
- OKTA $2,763,000,000.00
- Revenue This Year
- GMAB $22.68
- OKTA $11.92
- Revenue Next Year
- GMAB $15.85
- OKTA $9.48
- P/E Ratio
- GMAB $1.32
- OKTA $109.95
- Revenue Growth
- GMAB 32.97
- OKTA 12.68
- 52 Week Low
- GMAB $17.24
- OKTA $70.81
- 52 Week High
- GMAB $28.74
- OKTA $127.57
- Technical
- Relative Strength Index (RSI)
- GMAB 81.36
- OKTA 48.97
- Support Level
- GMAB $27.58
- OKTA $89.65
- Resistance Level
- GMAB $27.61
- OKTA $94.34
- Average True Range (ATR)
- GMAB 0.37
- OKTA 3.28
- MACD
- GMAB 0.26
- OKTA 0.30
- Stochastic Oscillator
- GMAB 97.02
- OKTA 35.42
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About OKTA Okta Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.